Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

Drugs

Volumn 70, Issue 12, 2010, Pages 1545-1577

  Carter, Natalie J ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Glatiramer acetate, general; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CLADRIBINE; CROSS REACTING ANTIBODY; CYCLOPHOSPHAMIDE; FINGOLIMOD; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GAMMA INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LAQUINIMOD; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNITOL; METHYLPREDNISOLONE; MITOXANTRONE; MYELIN BASIC PROTEIN; NATALIZUMAB; NEUTRALIZING ANTIBODY; PHENYTOIN; PLACEBO; TUMOR NECROSIS FACTOR;

ABSENTEEISM; ACUTE LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANTIGEN PRESENTING CELL; ANXIETY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD BRAIN BARRIER; BRONCHOSPASM; CELL MIGRATION; CELL PROLIFERATION; CEREBROSPINAL FLUID; CHEST TIGHTNESS; CLINICAL ASSESSMENT; CLINICAL STUDY; CLINICAL TRIAL; CLINICALLY ISOLATED SYNDROME; COGNITION; CONVULSION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; CYTOKINE RELEASE; DEPRESSION; DISABILITY; DISEASE COURSE; DISEASE DURATION; DOWN REGULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAM; EMBASE; FATIGUE; FEVER; FLUSHING; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEADACHE; HEART PALPITATION; HEREDITY; HUMAN; HYDROPHILICITY; HYPESTHESIA; IMAGE ENHANCEMENT; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; INCIDENCE; INFLUENZA; INFORMATION RETRIEVAL; INJECTION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INSOMNIA; LEUKOENCEPHALOPATHY; LIMB PAIN; LIPOATROPHY; LONG TERM CARE; LYMPHADENOPATHY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MULTIFOCAL LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARESTHESIA; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; POST HOC ANALYSIS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PREVALENCE; PUBLICATION; QUALITY OF LIFE; RATING SCALE; RECURRENT DISEASE; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SEX RATIO; SIDE EFFECT; SKIN NECROSIS; SUICIDE; SYSTOLIC DYSFUNCTION; T LYMPHOCYTE; TACHYCARDIA; TH1 CELL; THORAX PAIN; TREATMENT CONTRAINDICATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; URINARY TRACT INFECTION; URTICARIA; VISUAL ANALOG SCALE;

ADJUVANTS, IMMUNOLOGIC; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 77955442859     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204560-000000000-00000     Document Type: Review

References (124)

1. Behan PO, Chaudhuri A, Roep BO. The pathogenesis of multiple sclerosis revisited. J R Coll Physicians Edinb 2002; 32: 244-265
2. World Health Organization. Neurological disorders: a public health approach [online]. Available from URL: http://www.who.int/mental-health/ neurology/chapter-3- a-neuro-disorders-public-h-challenges.pdf [Accessed 2010 Jan 26]
3. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010 Mar; 9 (5): A387-94
4. Ryan M, Deno S, Zwibel HL. Review of the clinical debate regarding interventions for multiple sclerosis. J Manag Care Pharm 2009; 15 (Suppl. S-b): S1-17
5. Comi G, Martinelli V, Rodegher M, et al. Effect of glatir-amer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009 Oct 31; 374 (9700): 1503-1511
6. Tintore M. New options for early treatment of multiple sclerosis. J Neurol Sci 2009 Feb 1; 277 Suppl. 1: S9-11
7. Miller JR. The importance of early diagnosis of multiple sclerosis. J Manage Care Pharm 2004 Jun; 10 (3 Suppl. 2): S4-11
8. Chaudhuri A, Behan PO. Treatment of multiple sclerosis: beyond the NICE guidelines. QJM 2005 May; 98 (5): 373-378
9. Teva Pharmaceutical Ltd. Copaxone-the leading multiple sclerosis therapy [online]. Available from URL: http://www.tevapharm.com/copaxone/[Accessed 2010 May 26]
10. Teva Pharmaceuticals Ltd. Copaxone® (glatiramer acetate) solution for subcutaneous injection: US prescribing information highlights [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020622s057lbl.pdf [Accessed 2009 Nov 23]
11. Teva Pharmaceuticals Ltd. Copaxone® 20 mg/mL, solution for injection, pre-filled syringe: UK prescribing information [online]. Available from URL: http://emc.medicines. org.uk/medicine/17516/SPC/Copaxone+20mg+ml%2c+ Solution+For+Injection%2c+Pre-Filled+Syringe/[Accessed 2009 Nov 23]
12. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurother 2007 Oct; 4 (4): 647-653
13. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008 Mar; 255 Suppl. 1: 26-36
14. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs 2002; 16 (12): 825-850
15. Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS: fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol 2007; 36 245-253
16. Blanchette F. Clinical significance of glatiramer acetate antibodies. Mult Scler 2007 May; 13 Suppl. 1: S28-35
17. Farina C, Weber MS, Meinl E, et al. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005 Sep; 4 (9): 567-575
18. Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000 Jun 20; 97 (13): 7452-7457
19. Chen M, Gran B, Costello K, et al. Glatiramer acetate in-duces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001 Aug; 7 (4): 209-219
20. Chen M, Conway K, Johnson KP, et al. Sustained im-munological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 2002 Sep 15; 201 (1-2): 71-77
21. Duda PW, Schmied MC, Cook SL, et al. Glatiramer acet-ate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000 Apr; 105 (7): 967-976
22. Valenzuela RM, Kaufman MD, Russo PC, et al. Predictive biomarkers of clinical responses to glatiramer acetate therapy in multiple sclerosis [abstract no. P09.097]. Neurology 2009 Mar 17; 72 Suppl. 3: A469
23. Valenzuela RM, Rus H, Ito K, et al. Modulation of IL-18 and caspase-1 expression correlates with the clinical response to glatiramer acetate in multiple sclerosis [abstract no. P03.180]. Neurology 2006 Mar 14; 66 Suppl. 2: A75
24. Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998 Dec; 92 (1-2): 113-121
25. Sellebjerg F, Krakauer M, Hesse D, et al. T cell activation and Th2 cytokine secretion correlate with disease activity in multiple sclerosis patients treated with glatiramer acetate [abstract no. P09.104]. Neurology 2009 Mar 17; 72 Suppl. 3: A471
26. Hestvik ALK, Skorstad G, Price DA, et al. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler 2008 Jul; 14 (6): 749-758
27. Valenzuela RM, Balashov K, Ito K, et al. Time course and functional capacity of glatiramer acetate-induced regulatory T-cells in multiple sclerosis patients [abstract no. P233]. 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and the 12th Annual Conference of Rehabilitation in MS; 2007 Oct 11-14; Prague
28. Chiarini M, Sottini A, Ghidini C, et al. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate. Mult Scler 2010 Feb; 16 (2): 218-227
29. Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci US A 2009 Mar 17; 106 (11): 4355-4359
30. Li Q, Milo R, Panitch H, et al. Glatiramer acetate blocks the activation of THP-1 cells by interferon-y. Eur J Pharmacol 1998; 342: 303-310
31. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004 Jun 1; 172 (11): 7144-7153
32. Weber MS, Starck M, Wagenpfeil S, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004 Jun; 127 Pt 6: 1370-1378
33. Vieira PL, Heystek HC, Wormmeester J, et al. Glatiramer acetate (copolymer-1, Copaxone®) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003 May 1; 170 (9): 4483-4488
34. Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol 2006 Feb; 143 (2): 357-362
35. Jung S, Siglienti I, Grauer O, etal. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 2004 Mar; 148 (1-2): 63-73
36. Hussien Y, Sanna A, Soderstrom M, et al. Glatiramer acetate and IFN-P act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001 Dec; 121 (1-2): 102-110
37. Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006 May; 129 (5): 1293-1305
38. Chabot S, Yong FP, Le DM, et al. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler 2002 Aug; 8 (4): 299-306
39. Valenzuela RM, Sicsic C, Brenner T, et al. Correlation of glatiramer acetate (GA) antibodies and cytokine shifts with clinical response to GA in multiple sclerosis [abstract no. P01.053]. Neurology 2007 Mar 20; 68 Suppl. 1: A20
40. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008 Oct; 7 (10): 903-914
41. Aharoni R, Kayhan B, Eilam R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003 Nov 25; 100 (24): 14157-14162
42. Aharoni R, Eilam R, Domev H. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 2005 Dec 27; 102(52): 19045-19050
43. Aharoni R, Aizman E, Fuchs O, et al. Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in experimental autoimmune encephalomyelitis. J Neuroimmunol 2009 Oct; 215 (1-2): 73-83
44. Sarchielli P, Zaffaroni M, Floridi A, et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-P 1a, and high doses of immunoglobulins. Mult Scler 2007 Apr; 13 (3): 313-331
45. Blanco Y, Moral EA, Costa M, et al. Effect of glatiramer acetate (Copaxone®) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett 2006 Oct 6; 406 (3): 270-275
46. Azoulay D, Vachapova V, Shihman B, et al. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005 Oct; 167 (1-2): 215-218
47. Gilgun-Sherki Y, Panet H, Holdengreber V, et al. Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 2003 Oct; 47 (2): 201-207
48. Aharoni R, Arnon R, Eilam R. Neurogenesis and neuro-protection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005 Sep 7; 25 (36): 8217-8228
49. Aharoni R, Herschkovitz A, Eilam R, et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008 Aug 12; 105 (32): 11358-11363
50. Maier K, Kuhnert AV, Taheri N, et al. Effects of glatir-amer acetate and interferon-b on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol 2006 Oct; 169 (4): 1353-1364
51. Skihar V, Silva C, Chojnacki A, et al. Promoting oligo-dendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci USA 2009 Oct 20; 106 (42): 17992-17997
52. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001 Aug 28; 57 (4): 731-733
53. Arnold DL, Narayanan S, Antel S. Treatment with glatir-amer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial [abstract no. 17]. Mult Scler 2008 Sep; 14 Suppl. 1: S10
54. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005 Dec; 11 (6): 646-651
55. 1H-MRS monitoring in multiple sclerosis. J Neuroimaging 2008; 18: 314-319
56. Perumal JS, Hreha S, Shen Y, et al. Six-year prospective multi-voxel brain MRS study of two cohorts in RRMS to examine the effect of glatiramer acetate on neuronal/axonal metabolic injury [abstract no. P03.083]. Neurology 2009 Mar 17; 72 Suppl. 3: A143
57. Rieckmann P, Kallmann BA, Maeurer M, et al. The Val66Met BDNF polymorphism in multiple sclerosis: potential biomarker for treatment response to glatiramer acetate [abstract no. P07.126]. Neurology 2008 Mar 11; 70 Suppl. 1: A374
58. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial. Neurology 1995 Jul 1; 45 (7): 1268-1276
59. Ure DR, Rodriguez M. Polyreactive antibodies to glatir-amer acetate promote myelin repair in murine model of demyelinating disease. FASEB J 2002 Aug; 16 (10): 1260-1262
60. Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone®. J Neuroimmunol 2001 Apr; 115(1-2): 152-160
61. Karussis D, Teitelbaum D, Sicsic C, et al. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol 2010 Mar 30; 220 (1-2): 125-130
62. Comi G, Filippi M, Wolinsky JS, et al. European/Cana-dian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001 Mar; 49 (3): 290-297
63. Achiron A, Feldman A, Gurevich M. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis Markers 2009; 27: 63-73
64. Lobel E, Riven-Kreitman R, Amselem A, et al. Copoly-mer-1. Drugs Future 1996 Feb; 21 (2): 131-134
65. Neuhaus O, Kieseier BC, Hartung H-P. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007 Aug 15; 259 (1-2): 27-37
66. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assess-ment of glatiramer acetate in multiple sclerosis. Drug Saf 2001; 24 (13): 979-990 (Pubitemid 33097098)
67. Center for Drug Evaluation and Research. Clinical phar-macology and biopharmaceutics review: glatiramer acetate [online]. Available from URL ,http://www.accessdata. fda.gov/drugsatfda-docs/nda/2001/020622-S015-CO PAXONE-INJECTION-AP.pdf [Accessed 2010 Mar 29]
68. O'Connor P, Filippi M, Arnason B, et al. 250 (J.g or 500 (J.g interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009 Oct; 8 (10): 889-897
69. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009 Jun 9; 72 (23): 1976-1983
70. Plus supplementary material available from http://www.neurology.org [Accessed 2010 Feb 19]
71. Jongen PJH, Carton H, Sanders EACM, et al. FOCUS study: fatigue and quality of life in relapsing-remitting multiple sclerosis patients using glatiramer acetate improved at 6 and 12 months of treatment [abstract no. P234]. 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and the 12th Annual Conference of Rehabilitation in MS; 2007 Oct 11-14; Prague
72. Ziemssen T, Hoffman J, Apfel R, et al. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 2008; 6:67
73. Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-P-1b-treated multiple sclerosis patients. Acta Neurol Scand 2006 Jun; 113 (6): 378-386
74. Miller A, Spada V, Beerkircher D, et al. Long-term (up to 22 years), open-label, compassionate-use study of glatir-amer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2008 May; 14 (4): 494-499
75. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone®) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000 Feb 22; 54 (4): 813-817
76. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone®) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998 Mar 1; 50 (3): 701-708
77. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone®): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003 Dec; 9 (6): 585-591
78. Johnson KP, Ford CC, Lisak RP, et al. Neurologic con-sequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005 Jan; 111 (1): 42-47
79. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006 Jun; 12 (3): 309-320
80. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010 Mar; 16 (3): 342-350
81. Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 2007 Apr 15; 255 (1-2): 57-63
82. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 Jan 22; 58 (2): 169-178
83. Wolinsky JS, Comi G, Filippi M, et al. Copaxones®'s effect on MRI-monitored disease in relasping MS is reproducible and sustained. Neurology 2002 Oct 22; 59 (8): 1284-1286
84. Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001 Sep; 124(9): 1803-1812
85. Cadavid D, Cheriyan J, Skurnick J, et al. New acute and chronic black holes in multiple sclerosis patients randomized to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry 2009; 80: 1337-1343
86. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manage Care Pharm 2007 Apr; 13 (3): 245-261
87. Tappenden P, McCabe C, Chilcott J, et al. Cost-effective-ness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009 Jul 31; 12 (5): 657-665
88. Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-P and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004 Jun; 8 (27): 1-78
89. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 Nov 1; 33 (11): 1444-1452
90. Pardo G, Boutwell C, Conner J, et al. Effect of oral anti-histamine on local injection site reactions with self-administered glatiramer acetate. J Neurosci Nurs 2010 Feb; 42 (1): 40-46
91. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987 Aug 13; 317 (7): 408-414
92. Merck Serono Europe Limited. Rebif® (interferon beta-1a) for subcutaneous injection: EU summary of product characteristics [online]. Available from URL , http://www. ema.europa.eu/humandocs/PDFs/EPAR/Rebif/emea- com bined-h136en.pdf [Accessed 2010 Jan 27]
93. Serono Inc. Rebif® (interferon beta-1a) for subcutaneous injection: US prescribing information [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda- docs/label/2005/103780s5062lbl.pdf [Accessed 2010 Jan 27]
94. Bayer HealthCare Pharmaceuticals Inc. Betaseron® (interferon beta-1b) for subcutaneous injection: US prescribing information [online]. Available from URL: http://www.betaseron.com/prescribing-info.jsp [Accessed 2010 Jan 27]
95. Bayer Schering Pharma AG. Betaferon® (interferon beta-1b) for subcutaneous injection: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Betaferon/emea- combined-h081en.pdf [Accessed 2010 Jan 27]
96. Biogen Idec Limited. Avonex® (interferon beta-1a) for in-tramuscular injection: EU summary of product characteristics [online]. Available from URL, http://www.ema. europa.eu/humandocs/PDFs/EPAR/avonex/H-102-PI-en. pdf [Accessed 2010 Jan 27]
97. Biogen Idec Inc. Avonex® (interferon beta-1a) for intramus-cular injection: US prescibing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda- docs/label/2007/103628s5115lbl.pdf [Accessed 2010 Jan 27]
98. Association of British Neurologists. Revised, 2009) guidelines for prescribing in multiple sclerosis [online]. Available from URL , http://www.theabn.org/abn/userfiles/file/ABN-MS- Guidelines-2009-Final.pdf [Accessed 2010 Feb 1]
99. National Institute for Clinical Excellence. Multiple sclero-sis: management of multiple sclerosis in primary and secondary care [online]. Available from URL, http://www.nice.org.uk/nicemedia/pdf/cg008guidance.pdf [Accessed 2010 Jan 29]
100. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis: new aspects and practical application. J Neurol 2004 Nov; 251 (11): 1329-1339
101. Compston A, Coles A. Multiple sclerosis. Lancet 2008 Oct 25; 372(9648): 1502-1517
102. EMD Sorono Inc. Novantrone® (mitoxantrone) for injec-tion: US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/019297s030s031lbl.pdf [Accessed 2010 Feb 1]
103. Elan Pharma International Ltd. Tysabri® (natalizumab) 300 mg for injection: EU summary of product character-sitics [online]. Available from URL: http://www.ema.europa. eu/humandocs/PDFs/EPAR/tysabri/emea-combined-h603 en.pdf [Accessed 2010 Feb 1]
104. Elan Pharmaceuticals Inc. Tysabri® (natalizumab) injection for intravenous use: highlights of US prescribing information [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/label/2008/ 125104s0067lbl.pdf [Accessed 2010 Feb 1]
105. National Institute for Clinical Excellence. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis [online]. Available from URL, http://www.nice.org.uk/nicemedia/pdf/TA127Niceguidance. pdf [Accessed 2010 Feb 1]
106. Bertolotto A. Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci 2009 Feb 1; 277 Suppl. 1: S29-32
107. Marriott JJ, Miyasaki JN, Gronseth G, et al. Evidence re-port: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010 May 4; 74 (18): 1463-1470
108. Rammohan KW, Shoemaker J. Emerging multiple sclero-sis oral therapies. Neurology 2010; 74 Suppl. 1: S47-53
109. Carroll WM. Oral therapy for multiple sclerosis-sea change or incremental step? N Engl J Med 2010 Feb 4; 362 (5): 456-458
110. Giovannoni G, Comi G, Cook S, et al. A placebo-con-trolled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362 (5): 416-426
111. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362 (5): 387-401
112. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. NEngl J Med 2010 Feb 4; 362 (5): 402-415
113. Multiple Sclerosis Resource Centre. Cladribine (Mylinax) [online]. Available from URL, http://www.msrc.co.uk/index. cfm?fuseaction=show&pageid= 1629 [Accessed 2010 Feb 5]
114. Multiple Sclerosis Resource Centre. FTY720 (Fingolimod) [online]. Available from URL, http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid= 1309 [Accessed 2010 Feb 5]
115. EMD Serono. EMD Serono receives refuse to file letter from FDA on cladribine tablets new drug application [online]. Available from URL: http://www.emdserono. com/cmg.emdserono-us/en/images/20091130-Cladribine- FDA-Press%20Release%20English%20Final-US-tcm115-47509.pdf?Version= [Accessed 2010 Mar 26]
116. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-2092
117. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65 (3): 268-275
118. Petkau J, Reingold SC, Held U, et al. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 2008 Jul; 14 (6): 770-778
119. Daumer M, Neuhaus A, Morrissey S, et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 72: 705-711
120. Barkhof F, Filippi M. MRI-the perfect surrogate marker for multiple sclerosis? [letter]. Nat Rev Neurol 2009 Apr; 5 (4): 182-183
121. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009 Mar 3; 72 (9): 806-812
122. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006 Jun 13; 66 (11): 1696-1702 (Pubitemid 43964625)
123. Thrower BW. Clinically isolated syndromes: predicting and delaying multiple sclerosis. Neurology 2007 12 Jun; 68 Suppl. 4: S12-5
124. Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008 Dec 9; 71 Suppl. 3: S3-7